Header Logo

Connection

Michelle Callegan to Colony Count, Microbial

Back to Details
This is a "connection" page, showing publications Michelle Callegan has written about Colony Count, Microbial.
Michelle Callegan
Connection Strength
1.222
Colony Count, Microbial
  1. Contribution of Leukocidin ED to the Pathogenesis of Staphylococcus aureus Endophthalmitis. Invest Ophthalmol Vis Sci. 2025 May 01; 66(5):11.
    View in: PubMed
    Score: 0.238
  2. C-X-C Chemokines Influence Intraocular Inflammation During Bacillus Endophthalmitis. Invest Ophthalmol Vis Sci. 2021 11 01; 62(14):14.
    View in: PubMed
    Score: 0.187
  3. Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis. J Vis Exp. 2021 02 06; (168).
    View in: PubMed
    Score: 0.178
  4. S-layer Impacts the Virulence of Bacillus in Endophthalmitis. Invest Ophthalmol Vis Sci. 2019 09 03; 60(12):3727-3739.
    View in: PubMed
    Score: 0.161
  5. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv Ther. 2009 Apr; 26(4):447-54.
    View in: PubMed
    Score: 0.078
  6. A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis. Invest Ophthalmol Vis Sci. 2008 Oct; 49(10):4482-9.
    View in: PubMed
    Score: 0.074
  7. Role of swarming migration in the pathogenesis of bacillus endophthalmitis. Invest Ophthalmol Vis Sci. 2006 Oct; 47(10):4461-7.
    View in: PubMed
    Score: 0.066
  8. Bacillus endophthalmitis: roles of bacterial toxins and motility during infection. Invest Ophthalmol Vis Sci. 2005 Sep; 46(9):3233-8.
    View in: PubMed
    Score: 0.061
  9. In vitro pharmacodynamics of ofloxacin and ciprofloxacin against common ocular pathogens. Cornea. 2000 Jul; 19(4):539-45.
    View in: PubMed
    Score: 0.043
  10. Efficacy of tobramycin drops applied to collagen shields for experimental staphylococcal keratitis. Curr Eye Res. 1994 Dec; 13(12):875-8.
    View in: PubMed
    Score: 0.029
  11. Ciprofloxacin versus tobramycin for the treatment of staphylococcal keratitis. Invest Ophthalmol Vis Sci. 1994 Mar; 35(3):1033-7.
    View in: PubMed
    Score: 0.027
  12. Topical antibiotic therapy for the treatment of experimental Staphylococcus aureus keratitis. Invest Ophthalmol Vis Sci. 1992 Oct; 33(11):3017-23.
    View in: PubMed
    Score: 0.025
  13. Pseudomonas deficient in protease IV has significantly reduced corneal virulence. Invest Ophthalmol Vis Sci. 1997 Jul; 38(8):1535-42.
    View in: PubMed
    Score: 0.009
  14. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection. Infect Immun. 1997 May; 65(5):1571-8.
    View in: PubMed
    Score: 0.009
  15. Pseudomonas keratitis. The role of an uncharacterized exoprotein, protease IV, in corneal virulence. Invest Ophthalmol Vis Sci. 1996 Mar; 37(4):534-43.
    View in: PubMed
    Score: 0.008
  16. The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis. Jpn J Ophthalmol. 1996; 40(2):212-9.
    View in: PubMed
    Score: 0.008
  17. Growth and virulence of a complement-activation-negative mutant of Streptococcus pneumoniae in the rabbit cornea. Curr Eye Res. 1995 Apr; 14(4):281-4.
    View in: PubMed
    Score: 0.007
  18. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res. 1995 Mar; 14(3):229-34.
    View in: PubMed
    Score: 0.007
  19. Pseudomonas aeruginosa keratitis in leukopenic rabbits. Curr Eye Res. 1993 May; 12(5):461-7.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.